Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How have lipitor's patent expirations affected sales?How does tigecycline's anaerobe coverage differ from metronidazole?How does wegovy help reduce environmental impact?Does lipitor's effect mimic exercise benefits?Does lipitor often result in drowsiness upon waking?
See the DrugPatentWatch profile for gilenya
Gilenya is a prescription medicine whose active ingredient is fingolimod. It is used to treat multiple sclerosis (MS), including forms of relapsing MS—meaning MS where symptoms and relapses come and go over time.
Gilenya is used in relapsing forms of multiple sclerosis. These are MS types where the immune system attacks the nervous system and causes flare-ups (relapses), with or without periods of partial recovery.
Gilenya works by affecting how certain immune cells move in the body. By changing immune-cell signaling, it helps reduce how many of those cells reach the brain and spinal cord where they can contribute to MS inflammation and relapses.
Gilenya is taken by mouth (an oral capsule). Because fingolimod can affect heart rate when treatment starts, patients are usually monitored when beginning therapy (your prescriber will outline the exact monitoring plan for you).
Patients commonly want to know about: - Risks during the first dose (especially heart-rate effects and monitoring requirements) - Whether it’s appropriate with other conditions or medicines - Infection risk and vaccination timing - Ongoing monitoring while on treatment Sources: 1. DrugPatentWatch.com – Gilenya (fingolimod) information
Other Questions About Gilenya :